



16 August 2019

Company Announcements Office  
Australian Securities Exchange  
Level 6, 20 Bridge Street  
SYDNEY, NSW 2000

## **Profit Guidance** **Full Year to 30 June 2019**

Your board is pleased to advise that from preliminary accounts available, subject to final audit, that the Group is expected to achieve the following results for the year ended 30 June 2019:-

### **Revenue**

Consolidated revenue for the financial year just ended increased by 26% to S\$102.7m from S\$81.5m achieved in the previous corresponding year.

### **Net Results**

Consolidated net profits after tax for the full financial year just ended are expected to improve by approximately 109% to range between S\$1.0m to S\$2.0m, compared with a consolidated loss of S\$10.87m in the previous corresponding year.

In November 2018, the medical technology cluster was demerged from the Group. This cluster had suffered gestation costs of about S\$4m a year. The results for the financial year just ended have taken into account S\$1.3m of the pre-demergers loss of this cluster. Future Group's results will no longer be required to take such gestation costs into account.

The Group's businesses faced considerable head-winds caused by an on-going global trade war and geopolitical factors. The uncertainties generated worsened in the second half of the year and remain unabated, causing customers to hold back investments. This has resulted in excess capacities that dampen profit margin. The situation is not expected to improve soon.

Strong focus is being placed to transform existing businesses to differentiate ourselves from our competitors and to scale the value chain.

### **Confirmed Orders**

As at 30 June 2019, the Group's confirmed orders in hand totalled S\$96.3m (2018: S\$37.8m). Of the total orders, S\$63.7m are expected to be delivered in the financial year ending 30 June 2020 and S\$32.6m in the financial year ending 30 June 2021.

Yours faithfully  
ZICOM GROUP LIMITED

Sim Giok Lak  
Chairman